Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
November 21, 2023 16:30 ET
|
Certara
Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
September 19, 2023 08:15 ET
|
Certara
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to...
Lyophilization Services for Biopharmaceuticals Market worth $3.58 Billion by 2028 - Exclusive Report by The Insight Partners
September 04, 2023 10:08 ET
|
The Insight Partners
Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Lyophilization is a process of isolating a solid substance from a solution. It is also known as freeze-drying is a process. The process is carried by...
Certara Reports Second Quarter 2023 Financial Results
August 09, 2023 16:15 ET
|
Certara
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. ...
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
July 13, 2023 16:30 ET
|
Certara
PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of...
Certara Reports First Quarter 2023 Financial Results
May 08, 2023 16:15 ET
|
Certara
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. ...
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
April 27, 2023 08:00 ET
|
Certara
PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...
Mydecine Innovations Group Provides Corporate Update
April 03, 2023 06:00 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering...
Biopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight Partners
March 23, 2023 08:46 ET
|
The Insight Partners
New York, March 23, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Biopharmaceuticals Market Size, Share, Trends, Growth and Report Forecasts to 2028 - COVID-19 Impact and Global...
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
March 07, 2023 08:00 ET
|
Certara
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new...